Kura Oncology (NASDAQ:KURA – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Kura Oncology in a research report issued on ...

The Kenya Forest Service (KFS) has sent a scam alert to Kenyans over fraudulent individuals extorting bribes from them, ...

The rapidly expanding Kura Sushi opened its fifth New Jersey location on Feb. 25, bringing its automated service and good, ...

Kura Revolving Sushi Bar is the Critic’s Choice for Best Chain Restaurant in the 2025 Foodie Awards. See who the readers ...

Kura Oncology Inc (KURA) reports significant revenue growth and strategic progress in its Q4 2024 earnings call, setting the ...

Shares of Kura Sushi USA Inc. (KRUS) were in focus on Friday as the company received an analyst upgrade, but retail sentiment ...

SAN DIEGO — SAN DIEGO — Kura Oncology Inc. (KURA) on Wednesday reported a loss of $19.2 million in its fourth quarter. The San Diego-based company said it had a loss of 22 cents per share. The results ...

Kura Oncology (KURA) announced that on March 3, 2025, the Compensation Committee of the Company’s Board of Directors granted inducement awards ...